CuraTeQ Wins Fourth EU Biosimilar Approval

  Published 9 months ago

CuraTeQ secured EU marketing authorisation for Dazublys, its fourth biosimilar after recent approvals by 2025.

  • Dazublys joins Zefylti and Dyrupeg with EU approval, expanding CuraTeQ’s international biosimilar portfolio in 2025.
  • Previous approvals include Bevqolva (Dec 2024), Zefylti (May 2025), and Dyrupeg (June 2025), highlighting CuraTeQ’s rapid growth.
  • Aurobindo Pharma manufactures APIs, generics, and services, supporting CuraTeQ’s production capabilities worldwide for global markets.

You might like these

ABML Q2 FY26 Profit Falls, Revenue Drops

Andhra Offers $600M to Boost Electronics

Tata Comm Rises on Digital Growth

Canara Bank Rs 9.5k Crore Fundraising & Network Expansion

CMS Info Systems Rebrands

HGIEL Launches BESS SPV in Gujarat

India Index Options Turnover Dips Amid Jane Street Embargo

News that matters the most ⚡